[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.205.87.3. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
February 1987

Isotretinoin and Cutaneous Helper T-Cell Lymphoma (Mycosis Fungoides)

Author Affiliations

From the Sections of Hematology/Oncology (Drs Kessler, Jones, and Meyskens and Ms Booth) and Dermatology (Drs Levine and Lynch), Department of Internal Medicine, and Arizona Cancer Center, University of Arizona, Tucson. Dr Jones is now with the Charles A. Sammons Cancer Center, Baylor University Medical Center, Dallas.

Arch Dermatol. 1987;123(2):201-204. doi:10.1001/archderm.1987.01660260071016
Abstract

• Retinoids, including isotretinoin, have demonstrated antiproliferative and antineoplastic activity in laboratory and clinical trials. In a phase II trial, 25 patients with extensive mycosis fungoides were evaluated for response to isotretinoin. There was a 44% (11 patients) objective clinical response rate with three clinical complete responses without concomitant evidence of pathologic clearing of the disease. An additional 24% (six patients) showed a minor degree of clinical improvement. The median time to response was two months (range, 0.5 to eight months) and the median response duration was eight months or longer (range, one to 25 months). Chronic toxic reactions consisted primarily of drying of the skin and mucous membranes and resulted in dose reduction in the majority of patients. It is concluded that isotretinoin produces significant clinical benefit to some patients with mycosis fungoides.

(Arch Dermatol 1987;123:201-204)

×